NCT04809597

Brief Summary

The investigators showed in 2015 (Guichet et al) that the Notch1 pathway has an anti-proliferative role on glial brain tumors. In this project, the investigators investigated which genes downstream of Notch1 pathway activation produce the anti-proliferative effect. The investigators hypothesized that the SNAI2 and TAL1 genes act downstream of Notch1

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
10

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Jan 2012

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2012

Completed
9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2021

Completed
19 days until next milestone

Study Completion

Last participant's last visit for all outcomes

January 20, 2021

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

March 17, 2021

Completed
5 days until next milestone

First Posted

Study publicly available on registry

March 22, 2021

Completed
Last Updated

March 22, 2021

Status Verified

March 1, 2021

Enrollment Period

9 years

First QC Date

March 17, 2021

Last Update Submit

March 18, 2021

Conditions

Glioma

Keywords

pathologist-graded gliomas

Outcome Measures

Primary Outcomes (2)

  • Effect of Notch1 activation on Tal1

    highthroughput gene analysis (DNA arrays) with cells transduced with activated form of Notch1

    1 day

  • Snai2 gene and protein expression

    western blot for Tal1 and Snai2 in protein extracted from low grade and high gliomas

    1 day

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Cases with brain diffuse low grade and high grade gliomas (glioblastomas)

You may qualify if:

  • Patient ≥18 years old
  • Patient affected with brain glioma classified according to WHO 2016 classification

You may not qualify if:

  • Patient who reject the study protocol
  • Radiotheray or chemotherapy treatment

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Uhmontpellier

Montpellier, 34295, France

Location

MeSH Terms

Conditions

Glioma

Condition Hierarchy (Ancestors)

Neoplasms, NeuroepithelialNeuroectodermal TumorsNeoplasms, Germ Cell and EmbryonalNeoplasms by Histologic TypeNeoplasmsNeoplasms, Glandular and EpithelialNeoplasms, Nerve Tissue

Study Officials

  • Jean-Philippe Hugnot

    University Hospital, Montpellier

    STUDY DIRECTOR

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 17, 2021

First Posted

March 22, 2021

Study Start

January 1, 2012

Primary Completion

January 1, 2021

Study Completion

January 20, 2021

Last Updated

March 22, 2021

Record last verified: 2021-03

Locations

FR(1)